Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-10-18

FDA Approved: LABETALOL HYDROCHLORIDE — Supplemental Application (Biocon Pharma Inc.)

View source ↗

Summary

FDA approved Biocon Pharma Inc.'s supplemental application for Labetalol Hydrochloride, a generic beta-blocker used to treat hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Labetalol Hydrochloride (Labetalol hydrochloride)

Snippet

SUPPL AP for LABETALOL HYDROCHLORIDE (LABETALOL HYDROCHLORIDE)